Indivior Announces Inclusion in the S&P SmallCap 600® Index
Get Alerts INDV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 22.7%
Revenue Growth %: -7.1%
Join SI Premium – FREE
"Indivior's inclusion in the S&P SmallCap 600 index marks an important milestone for Indivior that further aligns our capital markets presence with our sharpened
The S&P SmallCap 600 Index is a stock market index established by Standard & Poor's that is designed to measure the performance of the small-cap segment of the market and is composed of 600 constituent companies in the
About Indivior
Indivior Pharmaceuticals works to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease. Building on its portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-inclusion-in-the-sp-smallcap-600-index-302647090.html
SOURCE Indivior PLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Yili Shares China's Whole-Value-Chain Dairy Symbiosis Model at FAO Global Conference
- Mitsubishi Electric to Support Relief Efforts Near Nepal–China Border Following Flooding and Debris Flows
- Ethereum Price Prediction: Could ETH Hit $3,000 Before AlphaPepe Turns a $0.03111 Entry Into $1?
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share